Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
In a study, immune detection of oral cancers is linked to obesity.
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
4.
Regular physical activity before cancer diagnosis may lower progression and death risks
5.
Alternative Medicine for Breast Cancer: Study Raises Concern
1.
What is Red Cell Distribution Width and Why Should You Care?
2.
Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights
3.
Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained
4.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part X
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation